PaweÅ, K Kunicki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4574805/publications.pdf

Version: 2024-02-01

840119 610482 29 926 11 24 citations h-index g-index papers 29 29 29 1134 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring, 2021, 43, 150-200.	1.0	89
2	Validated Simple HPLC-UV Method for Mycophenolic Acid (MPA) Monitoring in Human Plasma. Internal Standardization: Is It Necessary?. Molecules, 2021, 26, 7252.	1.7	2
3	Prediction of Free Mycophenolic Acid Concentrations and Free Fraction in Adult Lupus Nephritis Patients. Therapeutic Drug Monitoring, 2019, 41, 406-408.	1.0	1
4	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring, 2019, 41, 261-307.	1.0	374
5	Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients—implications for therapeutic drug monitoring. European Journal of Clinical Pharmacology, 2019, 75, 371-379.	0.8	12
6	Isotope–labeled versus analog internal standard in LC–MS/MS method for tacrolimus determination in human whole blood samples – A compensation of matrix effects. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1104, 220-227.	1.2	11
7	Free mycophenolic acid determination in human plasma ultrafiltrate by a validated liquid chromatography–tandem mass spectrometry method. Biomedical Chromatography, 2017, 31, e3976.	0.8	10
8	Platelet aggregation and the risk of stent thrombosis or bleeding in elective percutaneous coronary intervention patients. Blood Coagulation and Fibrinolysis, 2017, 28, 383-388.	0.5	1
9	Therapeutic Drug Monitoring of Everolimus. Therapeutic Drug Monitoring, 2016, 38, 143-169.	1.0	102
10	Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice. Therapeutic Drug Monitoring, 2016, 38, 170-189.	1.0	95
11	Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome. BMC Cardiovascular Disorders, 2016, 16, 252.	0.7	9
12	A Comparison of the Immunochemical Methods, PETINIA and EMIT, With That of HPLC-UV for the Routine Monitoring of Mycophenolic Acid in Heart Transplant Patients. Therapeutic Drug Monitoring, 2015, 37, 311-318.	1.0	22
13	Validation of an assay for quantification of free normetanephrine, metanephrine and methoxytyramine in plasma by high performance liquid chromatography with coulometric detection: Comparison of peak-area vs. peak-height measurements. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2015. 1002. 63-70.	1.2	8
14	Patency of infarct-related artery and platelet reactivity in patients with ST-segment elevation myocardial infarction. Cor Et Vasa, 2013, 55, e126-e130.	0.1	1
15	Simple HPLC method for cefazolin determination in human serum – validation and stability testing. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 911, 133-139.	1.2	23
16	A limited sampling strategy for estimating mycophenolic acid area under the curve in adult heart transplant patients treated with concomitant cyclosporine. Journal of Clinical Pharmacy and Therapeutics, 2009, 34, 89-101.	0.7	18
17	Mycophenolic Acid Concentrations Determined By Emit And HPLC In Heart Transplant Patients. Therapeutic Drug Monitoring, 2005, 27, 232.	1.0	O
18	A Limited Sampling Strategy For Estimating Mycophenolic Acid Area-under-the Curve In Adult Heart Transplant Patients Treated With Concomitant Cyclosporine. Therapeutic Drug Monitoring, 2005, 27, 238.	1.0	0

#	Article	IF	CITATIONS
19	Pharmacokinetics Of Cyclosporine: Measures In The Second Month And In More Than One Year After Heart Transplantation. Therapeutic Drug Monitoring, 2005, 27, 231.	1.0	O
20	Comparison Of Cefaclor Absorption Characteristics From The Suspension And Modified-release Tablets In Fast And Fed Condition. Therapeutic Drug Monitoring, 2005, 27, 231.	1.0	1
21	Pharmacokinetic Interaction Between Tacrolimus and Clarithromycin in a Heart Transplant Patient. Therapeutic Drug Monitoring, 2005, 27, 107-108.	1.0	27
22	The Variability Of Mycophenolic Acid Pharmacokinetics In The Second Month After Heart Transplantation. Therapeutic Drug Monitoring, 2005, 27, 231.	1.0	0
23	Plasma antioxidant activity and vascular dementia. Journal of the Neurological Sciences, 2002, 203-204, 195-197.	0.3	47
24	Simple and sensitive high-performance liquid chromatographic method for the determination of 1,5-benzodiazepine clobazam and its active metabolite N-desmethylclobazam in human serum and urine with application to 1,4-benzodiazepines analysis. Biomedical Applications, 2001, 750, 41-49.	1.7	19
25	Determination of loratadine in human plasma by high-performance liquid chromatographic method with ultraviolet detection. Biomedical Applications, 2001, 755, 331-335.	1.7	35
26	N-Acetylation and hydroxylation polymorphisms in type II diabetics with microvascular disturbances. European Journal of Clinical Pharmacology, 1997, 51, 431-435.	0.8	7
27	High Performance Liquid Chromatographic Analysis of Some Antiarrhythmic Drugs in Human Serum Using Cyanopropyl Derivatized Silica Phase. Journal of Liquid Chromatography and Related Technologies, 1996, 19, 1169-1181.	0.5	4
28	Debrisoquine hydroxylation in a Polish population. European Journal of Clinical Pharmacology, 1995, 47, 503-505.	0.8	8
29	S15.29 Glycosylation of haemoglobin in red blood cells of spontaneously hypertensive rats and normotensive Wistar-Kyoto rats. Glycoconjugate Journal, 1993, 10, 320-321.	1.4	0